CHITOSAN-COPPER HYDROGEL, METHODS OF PRODUCTION THEREOF, COMPOSITIONS COMPRISING IT, METHODS USING IT, A SURFACE OF AN OBJECT, FABRIC, NON-WOVEN FABRIC COVERED WITH IT AND USES OF THE CHITOSAN-COPPER HYDROGEL
The invention relates to a chitosan-copper hydrogel containing from 0.0008 mM to 300 mM of chitosan with a degree of chitosan deacetylation of at least 20%, saturation with copper(II) ions in an amount corresponding to from 5 to 100% of the total content of the reactive amino groups of chitosan and pH 7±1, which has a liquid form at the temperature above 80°C. The invention also relates to a method of production of chitosan-copper hydrogel, a method for covering a surface with chitosan-copper hydrogel, a surface, a fabric, a non-woven fabric covered with it, a pharmaceutical, veterinary, cosmetic or care composition comprising it, a composition with chitosan-copper hydrogel for covering surfaces in order to prevent the development, to inhibit the growth and kill bacteria, fungi, viruses, protozoa, various uses of chitosan-copper hydrogel including as a biocidal agent, antiseptic agent, antimicrobial agent, bacteriostatic agent, antiviral agent, fungicidal agent, an agent for covering, soaking and disinfection of surfaces, as well as a method for purifying aqueous solutions from microbiological contaminants using chitosan-copper hydrogel.
A61L 101/50 - Polysaccharides or derivatives thereof
2.
A NEW BACTERIAL STRAIN WEISSELLA CIBARIA, A COMPOSITION COMPRISING IT, A PHARMACEUTICAL COMPOSITION FOR USE, A DIETARY SUPPLEMENT, A PROBIOTIC PREPARATION, A BACTERIAL STARTER CULTURE FOR MAKING BREAD, SOURDOUGH, BREAD, A METHOD FOR THE PRODUCTION OF BREAD, A METHOD FOR MICROBIOLOGICAL PRODUCTION OF DEXTRAN, A BACTERIAL PREPARATION AND APPLICATIONS USING THIS STRAIN
An object of the invention is a new bacterial strain Weissella cibaria deposited as KKP 2094p, a composition containing it, a pharmaceutical composition for use as a medicine, a dietary supplement, a probiotic preparation, a bacterial starter culture for making bread, sourdough, bread, a method for the production of bread, a method for the microbiological production of dextran, a bacterial preparation and applications using this strain especially for the prevention and/or treatment, preferably the treatment of intestinal cancer, preferably colorectal cancer.
A21D 8/04 - Methods for preparing doughTreating dough prior to baking treating dough with microorganisms or enzymes
A21D 13/06 - Products with modified nutritive value, e.g. with modified starch content
3.
METHOD OF DIFFERENTIATING OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY, METHOD OF MONITORING A RESPONSE TO TREATMENT OF A CHRONIC KIDNEY DISEASE OR GLOMERULOP ATHY IN A SUBJECT AND A METHOD OF TREATMENT OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY
The object of the present invention is a method of diagnosis of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: (a) determination of the level of at least five, or at least six or at least seven protein markers selected from the group consisting of Ig gamma-2 chain C region (IGHG2), serum albumin (ALB), ceruloplasmin (CP), thrombin (F2), haptoglobin beta chain (HP), alpha-1-antitrypsin (SERPINA1), Ig kappa chain V-1 region HK102 (IGKV1-5), myoglobin (MB), alpha-1-acid glycoprotein 1 (ORM1), serotransferrin(TF), alpha-1 B-glycoprotein (A1 BG), Igkappa chain V-I region Daudi (P04432), ganglioside GM2 activator (GM2A), alpha-1-acid glycoprotein 2 (ORM2), zinc-alpha-2-glycoprotein (AZGP1), afamin (AFM), NHL repeat-containing protein 3 (NHLC3), inter-alpha-trypsin inhibitor heavy chain H2 (ITIH2); wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from said subject and (b) assigning a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy based on the results of the assay of step (a), wherein this involves: (i) determining the probability of the patient having a particular glomerulopathy based on the level of a first marker one of the markers determined in step (a), the probability being estimated based on the levels of said first marker determined in subjects known to have the particular glomerulopathy; (ii) determining the probability of the patient having a particular glomerulopathy based on the level of a second marker one of the markers determined in step (a), the probability being estimated based on the levels of said second marker determined in subjects known to have the particular glomerulopathy; (iii) conducting the calculations of (i) as required for further markers determined in step (a); (iv) determining the probability of the subject, providing the urine sample tested in step (a), having or being at a risk of each of the assessed glomerulopathies as a multiplication product of the corresponding probabilities obtained from each marker in (i)-(iii). A further object of the present invention is a method of monitoring a response to treatment, comprising the following steps: (a) determination of the level, at a first point in time, of at least five, or at least six or at least seven protein markers selected from the group consisting of Ig gamma-2 chain C region (IGHG2), serum albumin (ALB), ceruloplasmin (CP), thrombin (F2), haptoglobin beta chain (HP), alpha-1-antitrypsin (SERPINA1), Ig kappa chain V-1 region HK102 (IGKV1-5), myoglobin (MB), alpha-1-acid glycoprotein 1 (ORM1), serotransferrin (TF), alpha-1 B-glycoprotein (A1 BG), Ig kappa chain V-I region Daudi (P04432), ganglioside GM2 activator (GM2A), alpha-1-acid glycoprotein 2 (ORM2), zinc-alpha-2-glycoprotein (AZGP1), afamin (AFM), NHL repeat-containing protein 3 (NHLC3), inter-alpha-trypsin inhibitor heavy chain H2 (ITIH2); wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from a subject; (b) repeating the assay of step (a) at a later point in time after a period wherein the subject was undergoing a treatment; (c) assessing a response to said treatment by comparing the results of the assays of steps (a) and (b), wherein lower marker levels after treatment are indicative of a positive response to treatment. A further object of the present invention is a method of treatment of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: (a) determination of the level of at least five, or at least six or at least seven protein markers selected from the group consisting of Ig gamma-2 chain C region (IGHG2), serum albumin (ALB), ceruloplasmin (CP), thrombin (F2), haptoglobin beta chain (HP), alpha-1-antitrypsin (SERPINA1), Ig kappa chain V-1 region HK102 (IGKV1-5), myoglobin (MB), alpha-1-acid glycoprotein 1 (ORM1), serotransferrin (TF), alpha-1 B-glycoprotein (A1 BG), Ig kappa chain V-I region Daudi (P04432), ganglioside GM2 activator (GM2A), alpha-1-acid glycoprotein 2 (ORM2), zinc-alpha-2-glycoprotein (AZGP1), afamin (AFM), NHL repeat-containing protein 3 (NHLC3), inter-alpha-trypsin inhibitor heavy chain H2 (ITIH2); wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from said subject and (b) assigning a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy based on the results of the assay of step (a), wherein this involves: (i) determining the probability of the patient having a particular glomerulopathy based on the level of a first marker one of the markers determined in step (a), the probability being estimated based on the levels of said first marker determined in subjects known to have the particular glomerulopathy; (ii) determining the probability of the patient having a particular glomerulopathy based on the level of a second marker one of the markers determined in step (a), the probability being estimated based on the levels of said second marker determined in subjects known to have the particular glomerulopathy; (iii) conducting the calculations of (i) as required for further markers determined in step (a); (iv) determining the probability of the subject, providing the urine sample tested in step (a), having or being at a risk of each of the assessed glomerulopathies as a multiplication product of the corresponding probabilities obtained from each marker in (i)-(iii); (c) administering treatment against a chronic kidney disease (CKD) or glomerulopathy in the subject evaluated in step (b) as having or being at a risk of chronic kidney disease or glomerulopathy, according to the particular glomerulopathy determined in step (b) (iv).
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
4.
METHOD OF SCREENING FOR A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY METHOD OF MONITORING A RESPONSE TO TREATMENT OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY IN A SUBJECT AND A METHOD OF TREATMENT OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY
The object of the present invention is a method of diagnosis of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: (a) determination of the level of at least three or four or five protein markers selected from the group consisting of serum albumin (ALB), alpha-1-antitrypsin (serpinal), alpha-1-acid glycoprotein 1 (ORM1), serotransferrin (TF) and trefoil factor 1 (TFF), wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from said subject and (b) assigning a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy or not having nor being at a risk thereof based on the results of the assay of step (a), wherein this involves estimating a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy or not having nor being at a risk thereof based on the level of each of the marker levels determined in (a)), the probability being estimated based on the levels of each of the markers as determined in subjects known to suffer from a glomerulopathy or a chronic kidney disease; and determining the probability of the subject, providing the urine sample tested in step (a), having or being at a risk of a glomerulopathy or a chronic kidney disease or not having nor being at a risk thereof as a product of the corresponding probabilities obtained from each marker. A further object of the present invention is a method of monitoring a response to treatment of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: a) measurement of the level, at a first point in time, for three or four or five of the markers selected from a group consisting of serum albumin (ALB), alpha-1-antitrypsin (serpinal), alpha-1-acid glycoprotein 1 (ORM1), serotransferrin (TF) and trefoil factor 1 (TFF), wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from a subject; b) repeating the assay of step (a) at a later point in time after a period wherein the subject was undergoing a treatment; c) assessing a response to said treatment by comparing the results of the assays of steps (a) and (b), wherein lower marker levels after treatment are indicative of a positive response to treatment. A further object of the present invention is a method of treatment of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: (a) determination of the level of at least three or four or five protein markers selected from the group consisting of serum albumin (ALB), alpha-1-antitrypsin (serpinal), alpha-1-acid glycoprotein 1 (ORM1), serotransferrin (TF) and trefoil factor 1 (TFF), wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from said subject and (b) assigning a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy based on the results of the assay of step (a); (c) administering treatment against a chronic kidney disease (CKD) or glomerulopathy in the subject evaluated in step (b) as having or being at a risk of chronic kidney disease or glomerulopathy.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
5.
METHOD OF SCREENING FOR A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY, METHOD OF MONITORING A RESPONSE TO TREATMENT OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY IN A SUBJECT AND A METHOD OF TREATMENT OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATH
The object of the present invention is a method of diagnosis of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: (a) determination of the level of at least three or four or five protein markers selected from the group consisting of serum albumin (ALB), alpha-1 -antitrypsin (serpinal ), alpha- 1 -acid glycoprotein 1 (ORM1), serotransferrin (TF) and trefoil factor 1 (TFF), wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from said subject and (b) assigning a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy or not having nor being at a risk thereof based on the results of the assay of step (a), wherein this involves estimating a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy or not having nor being at a risk thereof based on the level of each of the marker levels determined in (a) ), the probability being estimated based on the levels of each of the markers as determined in subjects known to suffer from a glomerulopathy or a chronic kidney disease; and determining the probability of the subject, providing the urine sample tested in step (a), having or being at a risk of a glomerulopathy or a chronic kidney disease or not having nor being at a risk thereof as a product of the corresponding probabilities obtained from each marker. A further object of the present invention is a method of monitoring a response to treatment of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: a) measurement of the level, at a first point in time, for three or four or five of the markers selected from a group consisting of serum albumin (ALB), alpha- 1 -antitrypsin (serpinal), alpha- 1 -acid glycoprotein 1 (ORM1), serotransferrin (TF) and trefoil factor 1 (TFF), wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from a subject; b) repeating the assay of step (a) at a later point in time after a period wherein the subject was undergoing a treatment; c) assessing a response to said treatment by comparing the results of the assays of steps (a) and (b), wherein lower marker levels after treatment are indicative of a positive response to treatment. A further object of the present invention is a method of treatment of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: (a) determination of the level of at least three or four or five protein markers selected from the group consisting of serum albumin (ALB), alpha-1 -antitrypsin (serpinal ), alpha- 1 -acid glycoprotein 1 (ORM1), serotransferrin (TF) and trefoil factor 1 (TFF), wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from said subject and (b) assigning a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy based on the results of the assay of step (a); (c) administering treatment against a chronic kidney disease (CKD) or glomerulopathy in the subject evaluated in step (b) as having or being at a risk of chronic kidney disease or glomerulopathy.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
6.
METHOD OF SCREENING FOR A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY, METHOD OF MONITORING A RESPONSE TO TREATMENT OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY IN A SUBJECT AND A METHOD OF TREATMENT OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY
The object of the present invention is a method of diagnosis of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: (a) determination of the level of at least three or four or five protein markers selected from the group consisting of serum albumin (ALB), alpha-1 -antitrypsin (serpinal ), alpha- 1 -acid glycoprotein 1 (ORM1), serotransferrin (TF) and trefoil factor 1 (TFF), wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from said subject and (b) assigning a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy or not having nor being at a risk thereof based on the results of the assay of step (a), wherein this involves estimating a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy or not having nor being at a risk thereof based on the level of each of the marker levels determined in (a) ), the probability being estimated based on the levels of each of the markers as determined in subjects known to suffer from a glomerulopathy or a chronic kidney disease; and determining the probability of the subject, providing the urine sample tested in step (a), having or being at a risk of a glomerulopathy or a chronic kidney disease or not having nor being at a risk thereof as a product of the corresponding probabilities obtained from each marker. A further object of the present invention is a method of monitoring a response to treatment of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: a) measurement of the level, at a first point in time, for three or four or five of the markers selected from a group consisting of serum albumin (ALB), alpha- 1 -antitrypsin (serpinal), alpha- 1 -acid glycoprotein 1 (ORM1), serotransferrin (TF) and trefoil factor 1 (TFF), wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from a subject; b) repeating the assay of step (a) at a later point in time after a period wherein the subject was undergoing a treatment; c) assessing a response to said treatment by comparing the results of the assays of steps (a) and (b), wherein lower marker levels after treatment are indicative of a positive response to treatment. A further object of the present invention is a method of treatment of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: (a) determination of the level of at least three or four or five protein markers selected from the group consisting of serum albumin (ALB), alpha-1 -antitrypsin (serpinal ), alpha- 1 -acid glycoprotein 1 (ORM1), serotransferrin (TF) and trefoil factor 1 (TFF), wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from said subject and (b) assigning a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy based on the results of the assay of step (a); (c) administering treatment against a chronic kidney disease (CKD) or glomerulopathy in the subject evaluated in step (b) as having or being at a risk of chronic kidney disease or glomerulopathy.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
7.
METHOD OF DIFFERENTIATING OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY, METHOD OF MONITORING A RESPONSE TO TREATMENT OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY IN A SUBJECT ANDA METHOD OF TREATMENT OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATH
The object of the present invention is a method of diagnosis of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: (a) determination of the level of at least five, or at least six or at least seven protein markers selected from the group consisting of Ig gamma-2 chain C region (IGHG2), serum albumin (ALB), ceruloplasmin (CP), thrombin (F2), haptoglobin beta chain (HP), alpha-1-antitrypsin (SERPINA1), Ig kappa chain V-l region HK102 (IGKV1 -5), myoglobin (MB), alpha-1-acid glycoprotein 1 (ORM1), serotransferrin (TF), alpha-1 B-glycoprotein (A1 BG), Ig kappa chain V- I region Daudi (P04432), ganglioside GM2 activator (GM2A), alpha-1-acid glycoprotein 2 (ORM2), zinc-alpha-2-glycoprotein (AZGP1), afamin (AFM), NHL repeat-containing protein 3 (NHLC3), inter-alpha-trypsin inhibitor heavy chain H2 (ITIH2); wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from said subject and (b) assigning a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy based on the results of the assay of step (a), wherein this involves: (i) determining the probability of the patient having a particular glomerulopathy based on the level of a first marker one of the markers determined in step (a), the probability being estimated based on the levels of said first marker determined in subjects known to have the particular glomerulopathy; (ii) determining the probability of the patient having a particular glomerulopathy based on the level of a second marker one of the markers determined in step (a), the probability being estimated based on the levels of said second marker determined in subjects known to have the particular glomerulopathy; (iii) conducting the calculations of (i) as required for further markers determined in step (a); (iv) determining the probability of the subject, providing the urine sample tested in step (a), having or being at a risk of each of the assessed glomerulopathies as a multiplication product of the corresponding probabilities obtained from each marker in (i)-(iii). A further object of the present invention is a method of monitoring a response to treatment, comprising the following steps: (a) determination of the level, at a first point in time, of at least five, or at least six or at least seven protein markers selected from the group consisting of Ig gamma-2 chain C region (IGHG2), serum albumin (ALB), ceruloplasmin (CP), thrombin (F2), haptoglobin beta chain (HP), alpha-1-antitrypsin (SERPINA1), Ig kappa chain V-l region HK102 (IGKV1 -5), myoglobin (MB), alpha-1-acid glycoprotein 1 (ORM1), serotransferrin (TF), alpha-1 B-glycoprotein (A1 BG), Ig kappa chain V-l region Daudi (P04432), ganglioside GM2 activator (GM2A), alpha-1-acid glycoprotein 2 (ORM2), zinc-alpha-2-glycoprotein (AZGP1), afamin (AFM), NHL repeat- containing protein 3 (NHLC3), inter-alpha-trypsin inhibitor heavy chain H2 (ITIH2); wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from a subject; (b) repeating the assay of step (a) at a later point in time after a period wherein the subject was undergoing a treatment; (c) assessing a response to said treatment by comparing the results of the assays of steps (a) and (b), wherein lower marker levels after treatment are indicative of a positive response to treatment. A further object of the present invention is a method of treatment of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: (a) determination of the level of at least five, or at least six or at least seven protein markers selected from the group consisting of Ig gamma-2 chain C region (IGHG2), serum albumin (ALB), ceruloplasmin (CP), thrombin (F2), haptoglobin beta chain (HP), alpha- 1 -antitrypsin (SERPINA1), Ig kappa chain V-l region HK102 (IGKV1 -5), myoglobin (MB), alpha-1-acid glycoprotein 1 (ORM1), serotransferrin (TF), alpha-1 B-glycoprotein (A1 BG), Ig kappa chain V- I region Daudi (P04432), ganglioside GM2 activator (GM2A), alp...
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
8.
METHOD OF DIFFERENTIATING OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY, METHOD OF MONITORING A RESPONSE TO TREATMENT OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY IN A SUBJECT AND A METHOD OF TREATMENT OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY
The object of the present invention is a method of diagnosis of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: (a) determination of the level of at least five, or at least six or at least seven protein markers selected from the group consisting of Ig gamma-2 chain C region (IGHG2), serum albumin (ALB), ceruloplasmin (CP), thrombin (F2), haptoglobin beta chain (HP), alpha-1-antitrypsin (SERPINA1), Ig kappa chain V-l region HK102 (IGKV1 -5), myoglobin (MB), alpha-1-acid glycoprotein 1 (ORM1), serotransferrin (TF), alpha-1 B-glycoprotein (A1 BG), Ig kappa chain V- I region Daudi (P04432), ganglioside GM2 activator (GM2A), alpha-1-acid glycoprotein 2 (ORM2), zinc-alpha-2-glycoprotein (AZGP1), afamin (AFM), NHL repeat-containing protein 3 (NHLC3), inter-alpha-trypsin inhibitor heavy chain H2 (ITIH2); wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from said subject and (b) assigning a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy based on the results of the assay of step (a), wherein this involves: (i) determining the probability of the patient having a particular glomerulopathy based on the level of a first marker one of the markers determined in step (a), the probability being estimated based on the levels of said first marker determined in subjects known to have the particular glomerulopathy; (ii) determining the probability of the patient having a particular glomerulopathy based on the level of a second marker one of the markers determined in step (a), the probability being estimated based on the levels of said second marker determined in subjects known to have the particular glomerulopathy; (iii) conducting the calculations of (i) as required for further markers determined in step (a); (iv) determining the probability of the subject, providing the urine sample tested in step (a), having or being at a risk of each of the assessed glomerulopathies as a multiplication product of the corresponding probabilities obtained from each marker in (i)-(iii). A further object of the present invention is a method of monitoring a response to treatment, comprising the following steps: (a) determination of the level, at a first point in time, of at least five, or at least six or at least seven protein markers selected from the group consisting of Ig gamma-2 chain C region (IGHG2), serum albumin (ALB), ceruloplasmin (CP), thrombin (F2), haptoglobin beta chain (HP), alpha-1-antitrypsin (SERPINA1), Ig kappa chain V-l region HK102 (IGKV1 -5), myoglobin (MB), alpha-1-acid glycoprotein 1 (ORM1), serotransferrin (TF), alpha-1 B-glycoprotein (A1 BG), Ig kappa chain V-l region Daudi (P04432), ganglioside GM2 activator (GM2A), alpha-1-acid glycoprotein 2 (ORM2), zinc-alpha-2-glycoprotein (AZGP1), afamin (AFM), NHL repeat- containing protein 3 (NHLC3), inter-alpha-trypsin inhibitor heavy chain H2 (ITIH2); wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from a subject; (b) repeating the assay of step (a) at a later point in time after a period wherein the subject was undergoing a treatment; (c) assessing a response to said treatment by comparing the results of the assays of steps (a) and (b), wherein lower marker levels after treatment are indicative of a positive response to treatment. A further object of the present invention is a method of treatment of a chronic kidney disease (CKD) or glomerulopathy in a subject, comprising the following steps: (a) determination of the level of at least five, or at least six or at least seven protein markers selected from the group consisting of Ig gamma-2 chain C region (IGHG2), serum albumin (ALB), ceruloplasmin (CP), thrombin (F2), haptoglobin beta chain (HP), alpha- 1 -antitrypsin (SERPINA1), Ig kappa chain V-l region HK102 (IGKV1 -5), myoglobin (MB), alpha-1-acid glycoprotein 1 (ORM1), serotransferrin (TF), alpha-1 B-glycoprotein (A1 BG), Ig kappa chain V- I region Daudi (P04432), ganglioside GM2 activator (GM2A), alpha-1-acid glycoprotein 2 (ORM2), zinc-alpha-2-glycoprotein (AZGP1), afamin (AFM), NHL repeat-containing protein 3 (NHLC3), inter-alpha-trypsin inhibitor heavy chain H2 (ITIH2); wherein said markers also comprise the non-full-length fragments thereof, in a urine sample from said subject and (b) assigning a probability of the subject having or being at a risk of chronic kidney disease or glomerulopathy based on the results of the assay of step (a), wherein this involves: (i) determining the probability of the patient having a particular glomerulopathy based on the level of a first marker one of the markers determined in step (a), the probability being estimated based on the levels of said first marker determined in subjects known to have the particular glomerulopathy; (ii) determining the probability of the patient having a particular glomerulopathy based on the level of a second marker one of the markers determined in step (a), the probability being estimated based on the levels of said second marker determined in subjects known to have the particular glomerulopathy; (iii) conducting the calculations of (i) as required for further markers determined in step (a); (iv) determining the probability of the subject, providing the urine sample tested in step (a), having or being at a risk of each of the assessed glomerulopathies as a multiplication product of the corresponding probabilities obtained from each marker in (i)-(iii); (c) administering treatment against a chronic kidney disease (CKD) or glomerulopathy in the subject evaluated in step (b) as having or being at a risk of chronic kidney disease or glomerulopathy, according to the particular glomerulopathy determined in step (b) (iv).
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
9.
A FACTOR INCREASING EFFICIENCY OF A DNA VACCINE AGAINST A VIRUS, A PLASMID DNA FORMULATION, A DNA VACCINE, A METHOD OF OBTAINING A MODIFIED EXPRESSION VECTOR AND USE OF A NUCLEOTIDE SEQUENCE RECOGNISED BY THE NF KAPPA B FACTOR
The invention is related to a factor increasing efficiency of a DNA vaccine aimed against a virus, a plasmid DNA preparation, a DNA vaccine, a method of obtaining a modified 3NFKB expression vector and use of a nucleotide sequence recognised by NFKB. More particularly, the provided solution is related to use of a DNA sequence recognised by the NF kappa B nuclear transcription factor (NFKB,nuclear factor kappa B) in a vaccine in order to ensure effective vaccine plasmid transport into the nucleus and to enhance transcription levels of the introduced gene-coding a selected antigen.
The presented invention is related to a DNA vaccine against the H5N1 influenza virus, a modified nucleotide sequence and use of the modified nucleotide sequence in vaccine manufacturing. In more detail, the presented invention is related to use of a modification of an antigen coding sequence in order to increase efficiency of a DNA vaccine.
The presented invention is related to a vaccine, a pharmaceutical composition, a carrier for nucleic acids and for other biologically active substances, use of composition in vaccine manufacturing and use of cationic derivatives of PTAI in production of immunomodulating substances. More specifically, the presented invention is related to use of carriers based on cationic derivatives of polyprenols used as DNA vaccine carriers, easily transported and stored.
The subject of the invention is an influenza virus haemagglutinin antigen, an influenza vaccine comprising said antigen, a method of producing said antigen, and use of the antigen as stated above to produce an influenza vaccine. The invention involves a new method of producing said antigen, suitable for use in a vaccine. The outcome as stated in the invention leads to obtaining a highly immunogenic antigen, which does not require contact with the whole virus but just haemagglutinin. The vaccine as described in the invention does not contain the virus or its parts, does not contain cells coming from other organisms or their parts, but only purified haemagglutinin antigen.
UNIWERSYTET IM. ADAMA MICKIEWICZA W POZNANIU (Poland)
Inventor
Łukasik, Anna
Zielenkiewicz, Piotr
Szweykowska-Kulińska, Zofia
Pączek, Leszek
Nowaczyk, Maria
Abstract
The subject matter of the invention is a use of plant-derived miR172 molecule or its synthetic equivalent, selected from amongst miR172a or miR172b, for decreasing inflammatory processes in the organism, a method of decreasing B and T lymphocyte proliferation, as well as a method of reducing FAN (Factor Associated with Neutral Sphingomyelinase Activation) protein level. The goal of the present invention is to deliver a novel therapeutic method based on miRNA molecules, which through the interaction with mRNA encoding FAN protein, negatively regulate its expression and decrease the inflammatory response of the organism.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
14.
DNA vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the H5 haemagglutinin of an influenza virus and use of the DNA vaccine
The object of the invention is a DNA vaccine, method of inducing the immune response, antibodies specifically recognizing the haemagglutinin H5 of an influenza virus and application of the DNA vaccine. According to the invention, one or two-fold immunization of hens with DNA vaccine containing a cDNA encoding the modified H5 haemagglutinin HA protein, i.e. with the deletion of the cleavage site between HA subunits (this provides for greater safety of the vaccines). Moreover, the encoding region of the HA is modified in such a way that protein production in the bird cells should achieve maximal yield. The main modification is codon optimization for the hens and deletion of the site of proteolytic cleavage between subunits HA1 and HA2.
The present invention relates to a method of purification of waste water with a high content of metals, especially Ag and Cu, and a composition for use in this method. The method for purification of waste water with a high content of metals, consists of two step process, wherein in the first step a mixture of at least two water soluble salts and a polymer that is biodegradable and has high molecular mass - chitosan are used. Then the process comprises filtering off the resulted precipitate and in the second step adding again chitosan to the filtrate.
C02F 1/52 - Treatment of water, waste water, or sewage by flocculation or precipitation of suspended impurities
C02F 1/00 - Treatment of water, waste water, or sewage
16.
SYNTHETIC GENES ENCODING PEPTIDE FRAGMENTS OF NATURAL MYELIN PROTEINS FOR INDUCTION OF ORAL TOLERANCE, DNA FRAGMENT COMPRISING THESE GENES, MEANS OF OBTAINING THESE PEPTIDES IN A MICROBIAL (BACTERIAL) SYSTEM AND THEIR MEDICAL APPLICATION
The subject of the invention is the method of producing low molecular weight peptides, derivatives of the spinal cord myelin proteins, in bacteria, in particular lactic acid bacteria, to obtain single and combined preparations of myelin peptides for medical use, in particular for induction of oral tolerance.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
17.
SYNTHETIC GENES ENCODING PEPTIDE FRAGMENTS OF NATURAL MYELIN PROTEINS FOR INDUCTION OF ORAL TOLERANCE, DNA FRAGMENT COMPRISING THESE GENES, MEANS OF OBTAINING THESE PEPTIDES IN A MICROBIAL (BACTERIAL) SYSTEM AND THEIR MEDICAL APPLICATION
The subject of the invention is the method of producing low molecular weight peptides, derivatives of the spinal cord myelin proteins, in bacteria, in particular lactic acid bacteria, to obtain single and combined preparations of myelin peptides for medical use, in particular for induction of oral tolerance.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
18.
SYNTHETIC GENES ENCODING PEPTIDE FRAGMENTS OF NATURAL MYELIN PROTEINS FOR INDUCTION OF ORAL TOLERANCE, DNA FRAGMENT COMPRISING THESE GENES, MEANS OF OBTAINING THESE PEPTIDES IN A MICROBIAL (BACTERIAL) SYSTEM AND THEIR MEDICAL APPLICATION
The subject of the invention is the means of obtaining lactic acid bacteria strains containing gene(s) encoding heterologous haemagglutinin (HA) protein of the avian influenza virus and/or its variants: HA 1-568, HA17-568, HA17-522, HA1-568His, HA17-568His as well as the gene encoding the heterologous chicken interleukin 2(chlL-2) protein, the microbiological method of producing these proteins, lactic acid bacteria strain(s) carrying these gene (or genes), their application, immunogenic composition containing at least one of these strains, and an effective vaccine preparation against the avian influenza virus. Additionally, the subject of the invention is application of the ptcB gene promoter region to optimize the production of heterologous proteins, according to the invention (claim 7).
DNA VACCINE, METHOD OF INDUCING THE IMMUNE RESPONSE, METHOD OF IMMUNISATION, ANTIBODIES SPECIFICALLY RECOGNISING THE H5 HAEMAGGLUTININ OF AN INFLUENZA VIRUS AND USE OF THE DNA VACCINE
The object of the invention is a DNA vaccine, method of inducing the immune response, antibodies specifically recognising the haemagglutinin H5 of an influenza virus and application of the DNA vaccine. According to the invention, one or two-fold immunisation of hens with DNA vaccine containing a cDNA encoding the modified H5 haemagglutinin HA protein, i.e. with the deletion of the cleavage site between HA subunits (this provides for greater safety of the vaccines). Moreover, the encoding region of the HA is modified in such a way that protein production in the bird cells should achieve maximal yield. The main modification is codon optimisation for the hens and deletion of the site of proteolytic cleavage between subunits HA1 and HA2.
The present invention comprises recombinant DNA molecule, expression cassette, DNA vector, binary plasmid, plant cell and a method of polypeptide production in eukaryotic organism and use thereof. In more details, it provides the means, through using methods of genetic engineering, of obtaining plants with advantageous breeding features, particularly with increased tolerance to abiotic stresses including mineral deficiency or plants useful for monitoring the process of autophagy.
The present invention relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. The invention provides compositions, pharmaceutical preparations and methods of correcting the cellular alteration of a mutant CFTR protein wherein the CFTR mutation is a mutation AF508-CFTR, or another mutation of class II.
C07C 233/65 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
A61K 31/663 - Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
22.
VIRUS-LIKE PARTICLE VECTOR AS A POLYVALENT PLATFORM FOR INTRACELLULAR DELIVERY OF HIGH-MOLECULAR-WEIGHT THERAPEUTIC SUBSTANCES, METHOD FOR GENERATING A VIRUS LIKE PARTICLE VECTOR AND USE OF A VIRUS-LIKE PARTICLE VECTOR AND A PHARMACEUTICAL COMPOSITION CONTAINING SAID VIRUS-LIKE PARTICLE VECTOR
The invention relates to a virus-like particle vector, a method for production of said vector, use of said vector and a pharmaceutical composition containing said virus-like particle vector. More particularly, the invention relates to a protein virus-like-particle vector which is adenovirus dodecahedron (Dd) and delivering therapeutic substances belonging to classes of proteins, peptides, polysaccharides, nucleic acids, lipids, lipoproteins, or derivatives thereof, to mammalian cells. This invention allows for production of human or animal vaccines, delivery of antibodies, antitumour proteins, antitumour agents, nucleic acids, enzymes and immunosuppressive agents, as well as proteins/peptides and lipids determining specific tissue tropism or nucleic acids, to mammalian cells. According to the method of the invention, the WW domains that form a universal linker for the vector are derived from fungal proteins, especially from the proteins of yeast.
The embodiment of the invention is a virus-like particle vector, a process for the manufacture thereof, use of the virus-like particle vector and a pharmaceutical composition, which contains the virus-like particle vector. The vector is intended for the delivery of therapeutic agents into specific mammalian tissues, especially low molecular weight agents, in particular low molecular weight anti-cancer drugs into cancer tissues. More specifically, the invention relates to the virus-like particle vector, which constitutes an adenoviral dodecahedron with the therapeutic substance encapsulated or covalently linked.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
New medical use of anthracycline antibiotics derivatives of general formula 1 and 2, wherein R1 is hydrogen or methoxy group, R2 is hydrogen or hydroxy group, R3 is hydroxy group in an axial or equatorial orientation, R4 and R5 are hydrogen or methyl group, R6 is 1-phenylethyl group or R5 and R6 together with a nitrogen atom are N,N-diethyl, N,N-dipropyl or N,N-dibutyl group, or R5 and R6 together with a nitrogen atom form N,N-1',4'-tetramethylene, N,N-3'-oxa-1',5'- pentamethylene, N,N-1',5'-pentamethylene, N,N-1',6'-hexamethylene, N1N- 1',7'-heptamethylene, N,N-3'-methylaza-1',5'-pentamethylene or 1-indolinyl group, whereas if X is HCI molecule, the compound is hydrochloride of a derivative of general formula 1 or if X is 0, the compound is a derivative in a free base form of general formula 1 wherein, these derivatives are used as active ingredients for preparation of a medicine for treatment of viral infections, preferably for treatment of infection caused by hepatitis C virus (HCV) and the pharmaceutical composition.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
This invention relates to a method of hydrolysis of the peptide bond between R1 and B in a specific designed amino acid sequence R1BXJZR3R2, where R1 represents a polypeptide of interest, R2 represents a sequence capable of specific binding to another component or molecule or another domain which needs to be cleaved, R3 represents an optional short peptide sequence, B represents a residue capable of accepting an acyl group, J represents a residue capable of metal ion binding, and X and Z represent amino acid residues, wherein the said method is based on a novel molecular mechanism of peptide bond hydrolysis, occurring in a specific complex of this metal ion with the BXJZ sequence. This method can be used to remove BXJZR3R2 domains in recombinant polypeptides, such as sequences capable of specific binding to another component or molecule to yield pure, unmodified R1 polypeptides of interest. The intermediate hydrolysis product can be reacted with other compounds to obtain derivatives of polypeptides of interest modified covalently at the C-terminus.
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, INSERM (France)
INSTYTUT MEDYCYNY DOSWIADCZALNEJ I KLINICZNEJ (Poland)
Inventor
Kulikowski, Tadeusz
Bretner, Maria
Najda, Andzelika
Cova, Lucyna
Trepo, Christian
Narayan, Ramamurthy
Piasek, Andrzej
Lipniacki, Andrzej
Zagórski-Ostoja, Wlodzimierz
Abstract
New derivatives of 7-O-(3'amino-2',3',6'-trideoxy-&agr;,&bgr;,L- arabinoheksopiranosyl)-adriamycinone (epirubicin) presented at Formula 1, where R1, R2, R3 and R4 are the same and indicate hydrogen atom, alkyl group, isopropyl, alkenyl or alkinyl, especially acetyl or alkylcarbonyl group, all with alkyl chain containing 1 to 5 carbon atoms or dimethylformamidinyl group, at which if R1 and R4 indicate simultaneously hydrogen atom, then R3 indicates dimethylformamidinyl group. According to the invention, medical application of novel epirubicin derivatives is characterized by the fact, that derivatives presented at Formula 1 are used as active substances potently inhibiting hepatitis C virus (HCV) replication. Pharmaceutically acceptable form of the drug against hepatitis C virus (HCV) infections as active substance contains epirubicin derivatives presented at Formula (1), where R1, R2, R3 and R4 have above mentioned indications, eventually in the form of hydrochloride. According to invention, form of the drug ensures simultaneously low toxicity in Huh 7 and PBMC cells, therapeutic index (TI) better than for epirubicin, and lower than for epirubicin acute toxicity in vivo.
C07H 15/252 - Naphthacene radicals, e.g. daunomycins, adriamycins
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (France)
INSTYTUT MEDYCYNY DOSWIADCZALNEJ I KLINICZNEJ (Poland)
Inventor
Kulikowski, Tadeusz
Bretner, Maria
Najda, Andzelika
Cova, Lucyna
Trepo, Christian
Narayan, Ramamurthy
Piasek, Andrzej
Lipniacki, Andrzej
Zagorski-Ostoja, Wlodzimierz
Abstract
The present invention relates to novel derivatives of epirubicin, pharmaceutical composition comprising these derivatives, and uses of epirubicin and its derivative for treating HCV.
C07H 15/252 - Naphthacene radicals, e.g. daunomycins, adriamycins
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
patents
